10-Q: Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Update

Regulus Therapeutics Inc. has released its financial results for the third quarter of 2024, alongside updates on its clinical programs, particularly RGLS8429 for ADPKD.

Summary

• Regulus Therapeutics Inc. reported a net loss of $14.1 million for the third quarter of 2024, and a net loss of $33.6 million for the nine months ended September 30, 2024.
• The company's research and development expenses were $11.3 million for the quarter and $25.7 million for the nine-month period, primarily driven by the advancement of the RGLS8429 program.
• General and administrative expenses totaled $3.9 million for the quarter and $10.6 million for the nine-month period.
• As of September 30, 2024, Regulus had $87.3 million in cash, cash equivalents, and investments.
• The company believes its current resources will fund operations for at least the next 12 months.
• Regulus is actively developing RGLS8429, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
• The Phase 1b clinical trial for RGLS8429 has completed weight-based dosing and has enrolled a fourth cohort receiving a fixed dose of 300mg.
• Topline data from the fourth cohort is expected in early 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical trials and sufficient funding for the next 12 months, the company is still incurring significant losses and faces numerous risks. The sentiment is neutral to slightly negative due to the ongoing losses and dependence on future capital raises.

Positives

• The company has sufficient cash to fund operations for at least the next 12 months.
• The Phase 1b trial of RGLS8429 has progressed through multiple dose cohorts with positive topline results.
• The company has completed enrollment in the fourth cohort of the RGLS8429 trial.
• The company has secured a license agreement with The University of Texas at Southwestern Medical Center for technology related to miR-17 for ADPKD.

Negatives

• The company continues to incur significant losses, with a net loss of $14.1 million for the quarter and $33.6 million for the nine-month period.
• The company has no revenue from product sales and is dependent on raising additional capital.
• The company is reliant on third parties for manufacturing and clinical trial operations.

Risks

• The company's approach to drug discovery is novel and may not lead to marketable products.
• Clinical trials may not be successful, and regulatory approvals are not guaranteed.
• The company may face competition from other biotechnology and pharmaceutical companies.
• The company is subject to stringent and evolving laws and regulations related to data privacy and security.
• The company's stock price may be highly volatile.
• The company may need to raise additional capital, and there is no guarantee that it will be available on acceptable terms.

Future Outlook

The company anticipates reporting topline data from the fourth cohort of the RGLS8429 Phase 1b trial in early 2025 and believes its current resources will fund operations for at least the next 12 months.

Management Comments

• Based on our operating plans, we believe our cash, cash equivalents and investments will be sufficient to fund our planned operations for at least 12 months following the issuance of these financial statements.
• We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing.

Industry Context

The company is operating in the competitive biotechnology and pharmaceutical industry, focusing on microRNA therapeutics, a relatively new area of drug development. The company is targeting orphan kidney diseases, which often have unmet medical needs, and is competing with other companies developing treatments for these conditions.

Comparison to Industry Standards

• Regulus's financial position, with $87.3 million in cash and investments, is typical for a clinical-stage biotech company, but the burn rate of $33.6 million for the first nine months of 2024 indicates a need for continued fundraising.
• The company's focus on microRNA therapeutics is a novel approach, and there are no direct comparables in terms of approved drugs, making it difficult to benchmark against industry standards.
• The progress of RGLS8429 through Phase 1b trials is consistent with the development timelines of other early-stage biotech companies, but the lack of revenue and reliance on external funding is a common challenge.
• The company's reliance on third-party manufacturers and CROs is standard practice in the industry, but it introduces risks related to supply chain and clinical trial execution.

Related Party Transactions

• Stelios Papadopoulos, Ph.D., Chairman of the Company's board of directors, was a 2024 Purchaser under the March 2024 SPA and purchased 250,000 shares of common stock for $0.4 million.
• Stelios Papadopoulos, Ph.D., Chairman of the Company's board of directors, was a 2023 Purchaser under the April 2023 SPA and purchased 222,198 shares of common stock for $0.2 million.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity raises and potential loss of investment if the company is unable to commercialize its product candidates.
• Employees are subject to the risk of potential layoffs if the company is unable to secure additional funding.
• Patients with ADPKD may benefit from the development of RGLS8429 if it proves to be safe and effective.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will continue to advance the clinical development of RGLS8429.
• The company will report topline data from the fourth cohort of the RGLS8429 Phase 1b trial in early 2025.
• The company will seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing.

Key Dates

Keywords

Regulus Therapeutics, RGLS8429, ADPKD, microRNA, clinical trial, biopharmaceutical, oligonucleotide, Phase 1b, financial results, research and development